文献速递胸部肿瘤

简报:III期IPSOS研究中非小细胞肺癌铂类不耐受的后验验证

Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study.
PubMed 文献 · J Thorac Oncol · 2025-07-22

基于III期IPSOS研究的事后分析,在453例意向治疗人群中405例(89%)符合精选铂类不耐受标准。与单药化疗相比,阿替利珠单抗改善总生存(HR 0.78,95%CI 0.63-0.98),3/4级治疗相关不良事件更少(17.3% vs 34.3%),5级事件更少(0.8% vs 3.0%),患者报告健康相关生活质量稳定或改善。

要点

  • IPSOS研究中89%(405/453)的NSCLC患者符合精选铂类不耐受标准。
  • 精选铂类不耐受人群阿替利珠单抗较单药化疗改善总生存,HR 0.78(95%CI 0.63-0.98)。
  • 阿替利珠单抗组3/4级治疗相关不良事件17.3%(46/266)低于化疗组34.3%(46/134)。

核心结论

  • 该亚组分析提示,在精选铂类不耐受人群中,一线阿替利珠单抗提供长期总生存获益,与意向治疗人群结果一致,且与单药化疗相比安全性良好。
  • 精选铂类不耐受人群的筛选标准可能为临床实践中NSCLC的治疗选择提供结构化方法。

研究设计与样本

  • III期IPSOS研究(NCT03191786)的事后分析。
  • 患者为不适合铂双药化疗的IIIB或IV期NSCLC,按2:1随机接受阿替利珠单抗或单药化疗(长春瑞滨或吉西他滨)。
  • 精选铂类不耐受亚组定义为:ECOG体能状态3分、年龄大于80岁、ECOG体能状态2分合并相关合并症、或年龄70岁及以上合并相关合并症。
  • 意向治疗人群共453例,其中405例(89%)符合精选铂类不耐受标准。

主要发现

  • 与化疗相比,阿替利珠单抗改善总生存(未分层风险比0.78;95%置信区间:0.63-0.98)。
  • 阿替利珠单抗组3或4级治疗相关不良事件为46/266(17.3%),化疗组为46/134(34.3%)。
  • 阿替利珠单抗组5级治疗相关不良事件为2/266(0.8%),化疗组为4/134(3.0%)。
  • 阿替利珠单抗与患者报告健康相关生活质量的稳定或改善相关。

关键数值与推荐

  • 精选铂类不耐受标准:ECOG体能状态3分、年龄大于80岁、ECOG体能状态2分合并相关合并症、或年龄70岁及以上合并相关合并症。
  • 总生存未分层风险比0.78(95%置信区间:0.63-0.98),阿替利珠单抗组对比化疗组。
  • 3或4级治疗相关不良事件:阿替利珠单抗组46/266(17.3%)对比化疗组46/134(34.3%)。
  • 5级治疗相关不良事件:阿替利珠单抗组2/266(0.8%)对比化疗组4/134(3.0%)。

临床怎么用

  • 该亚组分析提示,在精选铂类不耐受的NSCLC人群中,一线阿替利珠单抗可提供长期总生存获益且安全性良好。
  • 精选铂类不耐受人群的筛选标准可能为临床实践中NSCLC的治疗选择提供结构化方法。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The phase III IPSOS study (NCT03191786) demonstrated that atezolizumab was associated with improved survival, stable patient-reported outcomes, and a favorable safety profile versus single-agent chemotherapy in patients with NSCLC ineligible for platinum-based chemotherapy. As no established consensus criteria for platinum ineligibility exist for NSCLC, we performed a post hoc analysis from IPSOS to evaluate clinical outcomes in a selected platinum-ineligible (sPI) population meeting a refined definition. METHODS: Patients with stage IIIB or IV NSCLC who were ineligible for platinum-doublet chemotherapy were randomized (2:1) to receive atezolizumab or single-agent chemotherapy (vinorelbine or gemcitabine). Patients in the sPI subgroup were defined as those with Eastern Cooperative Oncology Group performance status of 3, age older than 80 years, Eastern Cooperative Oncology Group performance status of 2 with relevant comorbidities, or age 70 years or older with relevant comorbidities. RESULTS: Of 453 patients from the IPSOS intention-to-treat population, 405 (89%) met sPI criteria. Compared with chemotherapy, atezolizumab improved overall survival (unstratified hazard ratio 0.78; 95% confidence interval: 0.63-0.98). Atezolizumab was associated with fewer grade 3 or 4 treatment-related adverse events (46 of 266 [17.3%] versus 46 of 134 [34.3%] with chemotherapy), grade 5 treatment-related adverse events (two of 266 [0.8%] versus four of 134 [3.0%]), and stabilization or improvement of patient-reported health-related quality of life. CONCLUSIONS: This subanalysis suggests that first-line treatment with atezolizumab provides long-term overall survival, consistent with the results from the intention-to-treat population, and a favorable safety profile compared with single-agent chemotherapy in the sPI population. In addition, the selection criteria for platinum ineligibility from the sPI population may provide a structured approach for treatment selection in NSCLC in clinical practice.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Schulz C, Reck M, et al. Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study. J Thorac Oncol. 2025. PMID: 40706710. doi:10.1016/j.jtho.2025.07.115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。